Antibody Information
General Information of This Antibody
| Antibody ID | ANI0BTCFU |
|||||
|---|---|---|---|---|---|---|
| Antibody Name | Thio-Tr (A121C) |
|||||
| Antibody Type | Monoclonal antibody (mAb) |
|||||
| Antibody Subtype | Humanized IgG1 |
|||||
| Antigen Name | Receptor tyrosine-protein kinase erbB-2 (ERBB2) |
Antigen Info | ||||
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
Thio-Tr (A121C)-BMPEO-DM1 [Investigative]
Obtained from the Model Organism Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 83.69% (Day 7) | High HER2 expression (HER2 +++) | ||
| Method Description |
An allograft was propagated from the Fo5 mmty transgenic mouse which does not respond to.or responds poorly to HERCEPTIN therapy. Subjects were treated once with ADC (10 mg/kg); and placebo PBS buffer control (Vehicle) andmonitored over 3 weeks.
|
||||
| In Vivo Model | Breast cancer model MMTV-HER2 Fo5 | ||||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 96.92% (Day 7) | High HER2 expression (HER2 +++) | ||
| Method Description |
An allograft was propagated from the Fo5 mmty transgenic mouse which does not respond to.or responds poorly to HERCEPTIN therapy. Subjects were treated once with ADC (21 mg/kg); and placebo PBS buffer control (Vehicle) andmonitored over 3 weeks.
|
||||
| In Vivo Model | Breast cancer model MMTV-HER2 Fo5 | ||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.